Follow this innovation
[ via 
] [?]
Enhancing Oncolytic Virus Expression to Safely Optimize Efficacy
University of Pittsburgh
posted on 11/21/2011
Investigators at the University of Pittsburgh have discovered that the combination of oncolytic virus and a specific chemokine ligand leads to the most effective oncolytic viral delivery, replication and spread inside of a tumor mass.
Suggested Uses
- Enhance existing vaccines to more effective therapeutic vaccines
- Minimize vaccine boosts
- Enhance safety and efficacy of all oncolytic viruses.
Advantages
- Technology is beyond proof-of-concept stage,
supported by laboratory results and early
clinical results - Low overall R&D and clinical trial costs to
enhance oncolytic vaccines - Can be applied to all oncolytic virus-based
vaccines
Detailed Description
The co-administration of this chemokine ligand resulted in a decrease in the clearance of the oncolytic virus from the cancer tissue and facilitated recruitment of tumor-associated macrophage and increased cytokine expression of (interleukin (IL)-10(hi)/ IL-12(low)) in the tumor microenvironment.
Stage of Development
1. Phase I clinical trials
2. Preclinical animal data and some human data is available.
Provisional Patent Application Filed
File Number: 2371
Disease: Cancer
This innovation currently is not available for online licensing. Please contact Michelle A. Booden at University of Pittsburgh for more information.
request more info
ProfileFind more innovations
